AXON’s Alzheimer Tau Vaccine Phase 1 Study Results Published in Lancet Neurology

BRATISLAVA, Slovakia–(BUSINESS WIRE)–AXON Neuroscience announced that the results of the first-in-man study of an active tau vaccine have been published in Lancet Neurology, a leading journal in the clinical neurology field. The results demonstrated an excellent safety and immunogenicity profile of AXON’s vaccine, AADvac1, which is intended to be the first disease-modifying tau treatment for Alzheimer’s disease.ENCOURAGING RESULTS OF THE AADVAC1 VACCINEThis first-in-man, first-in-class study was designed to assess safety and tolerability of the AADvac1 active vaccine in the treatment of patients with mild-to-moderate Alzheimer’s disease. The study was conducted in Austria with Professor Reinhold Schmidt from the Medical University Graz as the coordinating investigator.The vaccine displayed a very favourable safety profile. Targeting tau pathology via immunotherapy did not induce abnormal accumulation of fluid and inflammation in the brain commonly…


Link to Full Article: AXON’s Alzheimer Tau Vaccine Phase 1 Study Results Published in Lancet Neurology

Pin It on Pinterest

Share This

Join Our Newsletter

Sign up to our mailing list to receive the latest news and updates about homeAI.info and the Informed.AI Network of AI related websites which includes Events.AI, Neurons.AI, Awards.AI, and Vocation.AI

You have Successfully Subscribed!